Therapeutic potential of KCa3.1 blockers: Recent advances and promising trends

Heike Wulff, Neil A. Castle

Research output: Contribution to journalArticle

103 Citations (Scopus)

Abstract

The Ca2+-activated K+ channel KCa3.1 regulates membrane potential and calcium signaling in erythrocytes, activated T and B cells, macrophages, microglia, vascular endothelium, epithelia, and proliferating vascular smooth muscle cells and fibroblasts. KCa3.1 has therefore been suggested as a potential therapeutic target for diseases such as sickle cell anemia, asthma, coronary restenosis after angioplasty, atherosclerosis, kidney fibrosis and autoimmunity, where activation and excessive proliferation of one or more of these cell types is involved in the pathology. This article will review the physiology and pharmacology of K Ca3.1 and critically examine the available preclinical and clinical data validating KCa3.1 as a therapeutic target.

Original languageEnglish (US)
Pages (from-to)385-396
Number of pages12
JournalExpert Review of Clinical Pharmacology
Volume3
Issue number3
DOIs
StatePublished - May 2010

Fingerprint

Coronary Restenosis
Calcium-Activated Potassium Channels
Calcium Signaling
Vascular Endothelium
Microglia
Sickle Cell Anemia
Autoimmunity
Vascular Smooth Muscle
Angioplasty
Membrane Potentials
Smooth Muscle Myocytes
Atherosclerosis
Fibrosis
B-Lymphocytes
Asthma
Epithelium
Fibroblasts
Erythrocytes
Macrophages
Pharmacology

Keywords

  • Asthma
  • Atherosclerosis
  • Fibrosis
  • ICA-17043
  • K3.1
  • Restenosis
  • Sickle-cell disease
  • TRAM-34

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Therapeutic potential of KCa3.1 blockers : Recent advances and promising trends. / Wulff, Heike; Castle, Neil A.

In: Expert Review of Clinical Pharmacology, Vol. 3, No. 3, 05.2010, p. 385-396.

Research output: Contribution to journalArticle

@article{9361ee25d9fe40f5aea364c5913f4eb5,
title = "Therapeutic potential of KCa3.1 blockers: Recent advances and promising trends",
abstract = "The Ca2+-activated K+ channel KCa3.1 regulates membrane potential and calcium signaling in erythrocytes, activated T and B cells, macrophages, microglia, vascular endothelium, epithelia, and proliferating vascular smooth muscle cells and fibroblasts. KCa3.1 has therefore been suggested as a potential therapeutic target for diseases such as sickle cell anemia, asthma, coronary restenosis after angioplasty, atherosclerosis, kidney fibrosis and autoimmunity, where activation and excessive proliferation of one or more of these cell types is involved in the pathology. This article will review the physiology and pharmacology of K Ca3.1 and critically examine the available preclinical and clinical data validating KCa3.1 as a therapeutic target.",
keywords = "Asthma, Atherosclerosis, Fibrosis, ICA-17043, K3.1, Restenosis, Sickle-cell disease, TRAM-34",
author = "Heike Wulff and Castle, {Neil A.}",
year = "2010",
month = "5",
doi = "10.1586/ecp.10.11",
language = "English (US)",
volume = "3",
pages = "385--396",
journal = "Expert Review of Clinical Pharmacology",
issn = "1751-2433",
publisher = "Expert Reviews Ltd.",
number = "3",

}

TY - JOUR

T1 - Therapeutic potential of KCa3.1 blockers

T2 - Recent advances and promising trends

AU - Wulff, Heike

AU - Castle, Neil A.

PY - 2010/5

Y1 - 2010/5

N2 - The Ca2+-activated K+ channel KCa3.1 regulates membrane potential and calcium signaling in erythrocytes, activated T and B cells, macrophages, microglia, vascular endothelium, epithelia, and proliferating vascular smooth muscle cells and fibroblasts. KCa3.1 has therefore been suggested as a potential therapeutic target for diseases such as sickle cell anemia, asthma, coronary restenosis after angioplasty, atherosclerosis, kidney fibrosis and autoimmunity, where activation and excessive proliferation of one or more of these cell types is involved in the pathology. This article will review the physiology and pharmacology of K Ca3.1 and critically examine the available preclinical and clinical data validating KCa3.1 as a therapeutic target.

AB - The Ca2+-activated K+ channel KCa3.1 regulates membrane potential and calcium signaling in erythrocytes, activated T and B cells, macrophages, microglia, vascular endothelium, epithelia, and proliferating vascular smooth muscle cells and fibroblasts. KCa3.1 has therefore been suggested as a potential therapeutic target for diseases such as sickle cell anemia, asthma, coronary restenosis after angioplasty, atherosclerosis, kidney fibrosis and autoimmunity, where activation and excessive proliferation of one or more of these cell types is involved in the pathology. This article will review the physiology and pharmacology of K Ca3.1 and critically examine the available preclinical and clinical data validating KCa3.1 as a therapeutic target.

KW - Asthma

KW - Atherosclerosis

KW - Fibrosis

KW - ICA-17043

KW - K3.1

KW - Restenosis

KW - Sickle-cell disease

KW - TRAM-34

UR - http://www.scopus.com/inward/record.url?scp=77952557868&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952557868&partnerID=8YFLogxK

U2 - 10.1586/ecp.10.11

DO - 10.1586/ecp.10.11

M3 - Article

C2 - 22111618

AN - SCOPUS:77952557868

VL - 3

SP - 385

EP - 396

JO - Expert Review of Clinical Pharmacology

JF - Expert Review of Clinical Pharmacology

SN - 1751-2433

IS - 3

ER -